Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Omadacycline Oral Tablet
Omadacycline · 1 trial · 1 indication
Metagenome will be extracted from fecal samples of ME population and subjected to second-generation high-throughput sequencing. Bioinformatics will be employed to study the changes in the types of resistance-related genes of microbiota during the drug administration process in the microbiologically evaluable population. This outcome is based on second-generation high-throughput sequencing. the outcome is to test the genes to confirm the changes in types of microbial resistors in different stages.
Metagenome will be extracted from fecal samples of ME population and subjected to second-generation high-throughput sequencing. Bioinformatics will be employed to study the changes in the quantity of resistance-related genes of microbiota during the drug administration process in the microbiologically evaluable population.This outcome is based on second-generation high-throughput sequencing. the outcome is to test the gene to confirm the changes in quantity of microbial resistors in different stages .
Metagenome will be extracted from fecal samples of ME population and subjected to second-generation high-throughput sequencing. Bioinformatics will be employed to study the changes in the abundance of resistance-related genes of microbiota during the drug administration process in the microbiologically evaluable population.This outcome is based on second-generation high-throughput sequencing. the outcome is to test the genes to confirm the changes in abundance of microbial resistors in different stages.
| Arm | Type | Description |
|---|---|---|
| Moxifloxacin | ACTIVE_COMPARATOR | Moxifloxacin PO (400 mg)q24h D1-D10 |
| Omadacycline | EXPERIMENTAL | Omadacycline PO (450 mg) q24h D1-D2 PO (300 mg) q24h D3-D10 |
| Name | Type | Description |
|---|---|---|
| Moxifloxacin Oral Tablet | DRUG | 400mg per tablet |
| Omadacycline Oral Tablet | DRUG | 150 mg per tablet |
Inclusion Criteria: 1. Sign an Informed Consent Form (ICF) prior to the commencement of any study-related procedures. 2. Chinese healthy male and female subjects aged between 18 and 40 years (inclusive). 3. Body mass index (BMI) between 18.5 and 23.9 kg/m2 (inclusive). 4. Complete the stool sample ...
Omadacycline is a small molecule drug being developed by Zai Lab Limited under the ticker ZLAB. It is also known as omadacycline oral tablet. The compound is in Phase 1 clinical development, with one completed trial in healthy adult volunteers conducted in China.
Omadacycline is being developed by Zai Lab Limited, which trades under the ticker ZLAB. The company is responsible for the clinical program, including the completed Phase 1 trial in China.
Omadacycline is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are currently listed. The drug is investigational and has not been approved by the FDA for any indication.
Omadacycline has been studied in one completed Phase 1 trial, NCT06462326, titled "A Study to Compare the Effect of Omadacycline Versus Moxifloxacin in Healthy Adult Volunteers." The trial enrolled 24 healthy volunteers in China and was randomized, double-blind, and active-controlled.
Yes, omadacycline oral tablet is an alternative name for omadacycline. Both refer to the same small molecule drug being developed by Zai Lab Limited under ticker ZLAB.